Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS
Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This is a multicentre, open-label, randomised phase II trial comparing azacitidine
monotherapy with combined azacitidine and vorinostat in patients with newly diagnosed,
relapsed or refractory acute myeloid leukaemia or high risk myelodysplastic syndromes
ineligible for intensive chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
University of Birmingham
Collaborators:
Celgene Leukemia Research Fund Merck Sharp & Dohme Corp.